Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease.

Autor: Weninger S; FBRI Cambridge Massachusetts USA., Sperling B; H. Lundbeck A/S Copenhagen Denmark., Alexander R; Takeda Pharmaceuticals International Co. Cambridge Massachusetts USA., Ivarsson M; Rodin Therapeutics 300 Technology Square Cambridge Massachusetts USA., Menzies FM; Eli Lilly and Co, Erl Wood Manor Windlesham UK., Powchik P; United Neuroscience 9 Exchange Place, I. F. S. C Dublin Ireland., Weber CJ; Alzheimer's Association Chicago Illinois USA., Altar CA; Splice Therapeutics Bethesda Maryland USA., Crystal RG; Department of Genetic Medicine Weill Cornell Medicine New York New York USA., Haggarty SJ; Chemical Neurobiology Laboratory Center for Genomic Medicine Department of Neurology Massachusetts General Hospital and Harvard Medical School Boston Massachusetts USA., Loring J; Scripps Research Institute La Jolla California USA., Bain LJ; Independent Science Writer Elverson Pennsylvania USA., Carrillo MC; Alzheimer's Association Chicago Illinois USA.
Jazyk: angličtina
Zdroj: Alzheimer's & dementia (New York, N. Y.) [Alzheimers Dement (N Y)] 2020 Oct 12; Vol. 6 (1), pp. e12090. Date of Electronic Publication: 2020 Oct 12 (Print Publication: 2020).
DOI: 10.1002/trc2.12090
Abstrakt: As knowledge of Alzheimer's disease (AD) progression improves, the field has recognized the need to diversify the pipeline, broaden strategies and approaches to therapies, as well as delivery mechanisms. A better understanding of the earliest biological processes of AD/dementia would help inform drug target selection. Currently there are a number of programs exploring these alternate avenues. This meeting will allow experts in the field (academia, industry, government) to provide perspectives and experiences that can help elucidate what the pipeline looks like today and what avenues hold promise in developing new therapies across the stages of AD. The focus here is on Active Immunotherapies and Alternative Therapeutic Modalities. This topic includes active vaccines, antisense oligomers, and cell-based therapy among others, and highlights new clinical developments that utilize these modalities.
Competing Interests: Stacie Weninger is employed by FBRI LLC, a wholly owned subsidiary of FMR LLC. FMR LLC and its affiliates invest broadly in many companies, including life sciences and pharmaceutical companies. Robert Alexander is a full‐time employee of Takeda. FMM is an employee and shareholder of Eli Lilly and Co. Stephen J. Haggarty was or is a member of the scientific advisory board of Rodin Therapeutics, Psy Therapeutics, Frequency Therapeutics, and Souvien Therapeutics, none of which were involved in the publication. Stephen J. Haggarty has also received speaking or consulting fees from Amgen, AstraZeneca, Biogen, Merck, and Regenacy Pharmaceuticals, as well as sponsored research or gift funding from AstraZeneca, JW Pharmaceuticals, Juvenescence, and Vesigen unrelated to the content of this manuscript. Stephen J. Haggarty is an inventor on patent applications related to targeted protein degradation for tauopathies and other CNS disorders.
(© 2020 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.)
Databáze: MEDLINE
Externí odkaz: